MiMedx is Issued Four Additional U.S. Patents for Placental Tissue Grafts
Published: Feb 11, 2013
KENNESAW, Ga., Feb. 11, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its receipt of four new issued patents related to tissue grafts derived from the placenta. The U.S. Patent Office has issued to MiMedx U.S. Patent Number 8,357,403, "Placental Tissue Grafts," with a grant date of January 22, 2013. The U.S Patent Office has also issued to MiMedx the following three patents with a grant date of February 12, 2013: U.S. Patent Number 8,372,437, "Improved Placental Tissue Grafts"; U.S. Patent Number 8,372,438, "Method For Inhibiting Adhesion Formation Using Improved Placental Grafts"; and U.S. Patent Number 8,372,439, "Method For Treating a Wound Using Improved Placental Tissue Graft." The new patents relate to the Company's placental tissue allografts, including AmnioFix® and EpiFix® brand allografts.
"These four newly issued patents bring the total to five placental-based U.S. patents that we have recently been issued," said Parker H. "Pete" Petit, Chairman and CEO. "We are pleased with the pace of review and acceptance of our patent applications preserving the unique intellectual property of our proprietary AmnioFix® and EpiFix® technologies. At present, we have in excess of 20 additional patent applications that have been filed with the U.S. Patent Office relating to these technologies and our placental tissue allografts. We are encouraged about the prospects of receiving more significant patent issuances resulting from our filings."
Bill Taylor, President and COO, commented, "These newly issued patents represent only a portion of the unique aspects of our PURION® process for amniotic tissues and the resulting allografts. Our special processing and cleansing of the amniotic tissue is very gentle to the tissue, and allows us to preserve the critical wound healing characteristics that are inherent in the amniotic tissue, and this yields an allograft with remarkable healing capabilities. This process does not decellularize the tissue, but rather retains those growth factors and cytokines that are critical to healing."
The MiMedx allografts produced from the Company's proprietary PURION® Process for amniotic membrane tissue can be stored at room temperature for five years without the need for refrigeration or freezing. The grafts can be utilized right out of the package without a complicated thawing process. These critical qualities of the MiMedx allografts allow hospitals, clinics and surgeons to effectively manage their inventory of allografts.
About the Company
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary Purion® Process, to produce a safe, effective and minimally manipulated implant for homologous use. MiMedx® is the leading supplier of amniotic tissue, having supplied over 120,000 allografts to date to distributors and OEMs for application in the Wound care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the anticipated approval of pending patents related to placental tissue allografts utilizing the Company's PURION® process for amniotic tissues and the impact of the five year at room temperature shelf life of the Company's allografts on hospitals, clinics and surgeons more effectively managing their inventory of allografts. These statements are based on current information and belief, and are not guarantees of future performance. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the anticipated approval of pending patents related to placental tissue allografts utilizing the Company's PURION® process for amniotic tissues may not materialize as anticipated, the five year at room temperature shelf life of the Company's allografts may not impact the allograft inventory management of hospitals, clinics and surgeons as anticipated, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2011. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.
SOURCE MiMedx Group, Inc.